Hanmi Genentech obesity drug deal worth $2.3B reported
Hanmi Pharmaceutical has signed an exclusive, worldwide license with Genentech for HM17321, a long-acting UCN2 analog aimed at obesity that promises weight loss with muscle preservation, with Genentech taking over development from Phase 2 onward outside Korea. The deal could reach about $2.3 billion, including a $190 million upfront, up to $2.1 billion in milestones, and future royalties, subject to U.S. antitrust clearance and successful clinical progression.
Health · 14 sources · Aug 24, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About Genentech
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It operates as an independent subsidiary of holding company Roche. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.
Everything about Genentech →- Country
- United States
- Headquarters
- South San Francisco
- Inception
- 1976, April 7, 1976
- Website
- http://www.gene.com/